<p>阿斯利康（AstraZeneca PLC）（NASDAQ:AZN - 獲取免費報告）在週二交易前出現了跳空下跌。該股此前收於 71.43 美元，但開盤價為 67.14 美元。阿斯利康的最新交易價格為 66.72 美元，成交量為 2,053,509 股。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>現在可以購買的 5 只超賣股票</li>
</ul>
<p>最近，一些分析師對該公司發表了評論。TD Cowen 將阿斯利康的目標價從 90.00 美元上調至 95.00 美元，並在 8 月 12 日的報告中給予該公司 “買入” 評級。德意志銀行將阿斯利康的股票評級從 “持有” 下調至 “賣出”，該報告於 9 月 13 日發佈。最後，Erste Group Bank 在 9 月 11 日的研究報告中將阿斯利康的評級從 “持有” 上調至 “買入”。一位分析師給予該股票 “賣出” 評級，一位給予 “持有” 評級，七位給予 “買入” 評級，另外兩位給予 “強烈買入” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 89.75 美元。</p>
<p><strong>閲讀我們最新的阿斯利康股票分析</strong></p>
<h2>阿斯利康股價下跌 6.7%</h2>
<ul>
<li>抵禦市場：3 只市值巨頭股票飆升至新高</li>
</ul>
<p>該公司的市值為 2065.9 億美元，市盈率為 32.11，市盈增長比率為 1.32，貝塔值為 0.47。該公司的 50 日移動平均線為 78.87 美元，200 日移動平均線為 78.77 美元。公司的債務與股本比率為 0.69，速動比率為 0.69，流動比率為 0.89。</p>
<h2>對阿斯利康的對沖基金看法</h2>
<p>機構投資者和對沖基金最近增加或減少了對該公司的持股。Martin Investment Management LLC 在第三季度將其在阿斯利康的持股增加了 2.8%。Martin Investment Management LLC 目前擁有 284,204 股該公司的股票，價值 22,571,000 美元，此前在上個季度又購買了 7,615 股。Integrated Advisors Network LLC 在第三季度將其在阿斯利康的持股增加了 46.6%。Integrated Advisors Network LLC 目前擁有 43,610 股該公司的股票，價值 3,398,000 美元，此前在上個季度又購買了 13,860 股。Creative Planning 在第三季度將其在阿斯利康的持股增加了 8.0%。Creative Planning 目前擁有 224,751 股該公司的股票，價值 17,510,000 美元，此前在該期間又購買了 16,692 股。TD Asset Management Inc 在第一季度將其在阿斯利康的持股增加了 8.6%。TD Asset Management Inc 目前擁有 1,537,410 股該公司的股票，價值 104,160,000 美元，此前在上個季度又購買了 121,876 股。最後，Northcape Wealth Management LLC 在第二季度購買了阿斯利康的新頭寸，價值約 269,000 美元。20.35% 的股票由機構投資者持有。</p>
<h2>阿斯利康公司簡介</h2>
<p>（獲取免費報告）</p>
<ul>
<li>阿斯利康股價下跌，儘管每股收益超出預期並上調了指引</li>
</ul>
<p>阿斯利康 PLC 是一家生物製藥公司，專注於處方藥的發現、開發、生產和商業化。該公司的市場產品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵蓋心血管、腎臟、代謝和腫瘤領域。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過阿斯利康</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>Palantir 突破 50 美元，是否還有機會入場？</li>
<li>如何計算通貨膨脹率</li>
<li>內部人士購買信號顯示這 3 只股票有上漲潛力</li>
<li>複利及其在投資中的重要性</li>
<li>這兩大巨頭將與埃隆·馬斯克的 Starlink 競爭</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<p>→ 最後的邊界（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ"/></p>
<h2>你現在應該投資 1000 美元在阿斯利康嗎？</h2>
<p>在考慮阿斯利康之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而阿斯利康並不在名單上。</p>
<p>儘管阿斯利康目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿斯利康

<p>阿斯利康（NASDAQ:AZN）股票在交易前出現跳空下跌，開盤價為 0.14，前一交易日收盤價為 0.43。該股最後交易價格為 0.72，成交量超過 200 萬股。分析師的評級意見不一：TD Cowen 上調至 “買入”，德意志銀行下調至 “賣出”，Erste Group Bank 上調至 “買入”。市場共識評級為 “適度買入”，目標價為 0.75。機構投資者持有該股票的 20.35%。阿斯利康專注於生物製藥，市值為 59 億美元，市盈率為 32.11</p>

<p>Shares of AstraZeneca PLC (NASDAQ:AZN - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $71.43, but opened at $67.14. AstraZeneca shares last traded at $66.72, with a volume of 2,053,509 shares changing hands.</p>
<div class="lb-trans"><p>阿斯利康（AstraZeneca PLC）（NASDAQ:AZN - 獲取免費報告）在週二交易前出現了跳空下跌。該股此前收於 71.43 美元，但開盤價為 67.14 美元。阿斯利康的最新交易價格為 66.72 美元，成交量為 2,053,509 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>5 Oversold Stocks to Buy Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在可以購買的 5 只超賣股票</li>
</ul>
</div><p>A number of analysts have recently commented on the company. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the company a &#34;buy&#34; rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Friday, September 13th. Finally, Erste Group Bank raised AstraZeneca from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $89.75.</p>
<div class="lb-trans"><p>最近，一些分析師對該公司發表了評論。TD Cowen 將阿斯利康的目標價從 90.00 美元上調至 95.00 美元，並在 8 月 12 日的報告中給予該公司 “買入” 評級。德意志銀行將阿斯利康的股票評級從 “持有” 下調至 “賣出”，該報告於 9 月 13 日發佈。最後，Erste Group Bank 在 9 月 11 日的研究報告中將阿斯利康的評級從 “持有” 上調至 “買入”。一位分析師給予該股票 “賣出” 評級，一位給予 “持有” 評級，七位給予 “買入” 評級，另外兩位給予 “強烈買入” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 89.75 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AZN</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的阿斯利康股票分析</strong></p>
</div><h2>AstraZeneca Trading Down 6.7 %</h2>
<div class="lb-trans"><h2>阿斯利康股價下跌 6.7%</h2>
</div><ul>
<li>Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>抵禦市場：3 只市值巨頭股票飆升至新高</li>
</ul>
</div><p>The firm has a market cap of $206.59 billion, a P/E ratio of 32.11, a P/E/G ratio of 1.32 and a beta of 0.47. The firm has a fifty day moving average of $78.87 and a 200-day moving average of $78.77. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.</p>
<div class="lb-trans"><p>該公司的市值為 2065.9 億美元，市盈率為 32.11，市盈增長比率為 1.32，貝塔值為 0.47。該公司的 50 日移動平均線為 78.87 美元，200 日移動平均線為 78.77 美元。公司的債務與股本比率為 0.69，速動比率為 0.69，流動比率為 0.89。</p>
</div><h2>Hedge Funds Weigh In On AstraZeneca</h2>
<div class="lb-trans"><h2>對阿斯利康的對沖基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Martin Investment Management LLC grew its position in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company's stock valued at $22,571,000 after buying an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company's stock worth $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning lifted its position in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company's stock worth $17,510,000 after purchasing an additional 16,692 shares during the period. TD Asset Management Inc raised its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company's stock worth $104,160,000 after buying an additional 121,876 shares in the last quarter. Finally, Northcape Wealth Management LLC bought a new position in AstraZeneca during the second quarter valued at about $269,000. 20.35% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該公司的持股。Martin Investment Management LLC 在第三季度將其在阿斯利康的持股增加了 2.8%。Martin Investment Management LLC 目前擁有 284,204 股該公司的股票，價值 22,571,000 美元，此前在上個季度又購買了 7,615 股。Integrated Advisors Network LLC 在第三季度將其在阿斯利康的持股增加了 46.6%。Integrated Advisors Network LLC 目前擁有 43,610 股該公司的股票，價值 3,398,000 美元，此前在上個季度又購買了 13,860 股。Creative Planning 在第三季度將其在阿斯利康的持股增加了 8.0%。Creative Planning 目前擁有 224,751 股該公司的股票，價值 17,510,000 美元，此前在該期間又購買了 16,692 股。TD Asset Management Inc 在第一季度將其在阿斯利康的持股增加了 8.6%。TD Asset Management Inc 目前擁有 1,537,410 股該公司的股票，價值 104,160,000 美元，此前在上個季度又購買了 121,876 股。最後，Northcape Wealth Management LLC 在第二季度購買了阿斯利康的新頭寸，價值約 269,000 美元。20.35% 的股票由機構投資者持有。</p>
</div><h2>AstraZeneca Company Profile</h2>
<div class="lb-trans"><h2>阿斯利康公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance</li>
</ul>
<div class="lb-trans"><ul>
<li>阿斯利康股價下跌，儘管每股收益超出預期並上調了指引</li>
</ul>
</div><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p>
<div class="lb-trans"><p>阿斯利康 PLC 是一家生物製藥公司，專注於處方藥的發現、開發、生產和商業化。該公司的市場產品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵蓋心血管、腎臟、代謝和腫瘤領域。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than AstraZeneca</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Palantir Cracks $50, Is There Still Time to Get on Board?</li>
<li>How to Calculate Inflation Rate</li>
<li>Insider Buying Signals Upside for These 3 Stocks</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>These 2 Big Players Are Set to Compete With Elon Musk’s Starlink</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過阿斯利康</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>Palantir 突破 50 美元，是否還有機會入場？</li>
<li>如何計算通貨膨脹率</li>
<li>內部人士購買信號顯示這 3 只股票有上漲潛力</li>
<li>複利及其在投資中的重要性</li>
<li>這兩大巨頭將與埃隆·馬斯克的 Starlink 競爭</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><p>→ The Final Frontier (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 最後的邊界（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10225&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AstraZeneca right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在阿斯利康嗎？</h2>
</div><p>Before you consider AstraZeneca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮阿斯利康之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而阿斯利康並不在名單上。</p>
</div><p>While AstraZeneca currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管阿斯利康目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

阿斯利康（NASDAQ:AZN）股價跳空下跌 - 以下是原因